Evaluation of Apparent Diffusion Coefficient as a Predictor of Grade Reclassification in Men on Active Surveillance for Prostate Cancer

Urology. 2020 Apr:138:84-90. doi: 10.1016/j.urology.2020.01.001. Epub 2020 Jan 15.

Abstract

Objective: To evaluate the association between apparent diffusion coefficient (ADC) on initial multiparametric MRI (mpMRI) and biopsy grade reclassification (GR) to grade group (GG) ≥2 prostate cancer (CaP) in men on active surveillance (AS) with GG 1 CaP.

Methods: We retrospectively identified 242 AS patients with reported ADC values on their initial mpMRI. ADC value from the index lesion was assessed as an independent predictor of GR using a Cox model. To ease clinical interpretation, we used a log-rank test to establish an ADC cutoff of 1128 × 10-6 mm2/s for Kaplan-Meier analysis.

Results: Of the 242 men, 70 underwent GR following initial mpMRI, of which 26 (37%) had GR at the index lesion. There was no significant difference in the median interval between biopsies for men with and without GR (P >.9). Men with GR had significantly lower median ADC than those without GR (P = .01). In multivariable analysis adjusting for age, prostate-specific antigen density, and National Comprehensive Cancer Network risk group, a 100-unit decrease in ADC was associated with a 12% increase in the risk of GR (HR = 1.12, 95% CI: 1.01-1.22, P = .03). Two- and 4-year rates of freedom from GR were significantly lower for men with ADC <1128 × 10-6 mm2/s vs ADC ≥1128 × 10-6 mm2/s (62% and 42% vs 78% and 68%, respectively; P <.001).

Conclusion: For AS patients, lower ADC on initial mpMRI index lesion is associated with increased risk of GR to GG ≥2 CaP and would be a useful component of multivariable risk prediction tools.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Biopsy
  • Feasibility Studies
  • Humans
  • Male
  • Middle Aged
  • Multiparametric Magnetic Resonance Imaging / methods*
  • Neoplasm Grading
  • Prostate / diagnostic imaging*
  • Prostate / pathology
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / pathology
  • Retrospective Studies
  • Risk Assessment / methods
  • Watchful Waiting / methods*